Calcipotriol-betamethasone aerosol foam,
does it really help with PGA treatment success versus the same ingredients in gel?
research showsThe grade is C. PGA success was 38% with four weeks of foam versus 22% with eight weeks of gel, an absolute difference of +16 points. PGA is a surrogate capped at C; LEO Pharma sponsorship and employee authors give I0, and the short endpoint adds one listed limitation, for C with 50 points.
ads claimDaivobet- and Enstilar-family products are prescribed in Korea. Faster or more convenient foam use should not be promoted as superiority of the medication itself.
Useful facts when choosing a product
- Both formulations contained calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g.
- PGA success was 38% versus 22%, absolute difference +16 points, P<.001.
- Verdict 1342 is B 76; 1796 C 56; 1814 C 56; 1815 C 54; 1836 C 56; 1895 C 54; and 1896 C 54. Those address systemic drugs, phototherapy, or other topical agents; this verdict compares formulations of the same drug.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.calcipotriol-betamethasone-aerosol-foam.UNK.pga-treatment-success.treat.UNKUnknown > Calcipotriol-betamethasone aerosol foam > Unknown > PGA treatment success > Treatment or remission claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The allocation quote is: "Treatment was assigned via a central Interactive Web Response System (IWRS) in accordance with a computer-generated randomization schedule; randomization was stratified by trial site and baseline disease severity (two strata: mild; at least moderate)." It was investigator-blinded and included vehicle groups. Defect name: Short primary comparison. Listed item: Short duration (under 12 weeks) - PGA compared foam at week 4 with gel at week 8. Avoidability: Avoidable - both formulations could be compared at the same endpoint at 12 weeks or later. Attrition was 10.2% (47/463), with 416/463 completing, below 15%. Funding, conflicts, and acknowledgments identify LEO Pharma sponsorship, DL and BB as company employees, and LEO-funded medical writing by Mudskipper Business Ltd, giving I0.
Why this is classified as C (50)
A PGA surrogate, manufacturer-only I0 evidence, one short-duration limitation, and one E+ strength give C with 50 points.
Counterpoint. Higher PGA success does not establish longer remission, better quality of life, or reduced cumulative steroid harm.
Rejudgment record. Cross-check applied — PGA surrogate, manufacturer sponsorship and employee authors, and short formulation comparison
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Short-term PGA success versus same-ingredient gel | C | 38% versus 22%, an absolute difference of +16 points. |
| Long-term remission and reduced steroid harm | ? | Not established. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Paul C et al. 2017 PSO-ABLE | Investigator-blinded phase 3 randomized four-group trial | 463; 416 completed | Sponsored by LEO Pharma; DL and BB were employees; other relationships were disclosed; medical writing was also company funded | PGA clear/almost clear with at least two-grade improvement; foam at week 4 versus gel at week 8 | 38% versus 22%, absolute difference +16 points, P<.001 | Single short-term manufacturer-sponsored PGA formulation comparison |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Calcipotriol-betamethasone aerosol foam benefits PGA treatment success versus gel in plaque psoriasis - benefit — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/calcipotriol-betamethasone-foam-versus-gel-pga-psoriasis/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.